Loading...

About Carolina BioOncology Institute

Carolina BioOncology Institute is reimagining access to groundbreaking cancer treatments, a disruptive approach to bench-to-bedside medicine. Our unique business model leverages curated access to Phase I Clinical Trials with on site research and clinical laboratory support for the treatment of human disease.

Patient & Sponsor Services

Clinical Trials

Patients participating in a clinical trial have the opportunity to receive new research treatments before they are widely available. With Phase I clinical trial capabilities at our facility in Huntersville, NC, we’re able to quickly enroll patients in the newest trials and provide the highest quality of patient care in a community-based setting.

Learn More

CLIA Laboratory Services

Our on site Clinical Laboratory can provide routine patient sample analyses including hematology, urinalysis, metabolic testing, and other diagnostic services. The facility is also high-complexity certified in Immunology and can perform CELLSEARCH CTC enumeration and COVID-19 screening as requested or provider-ordered.

Learn More

Contract Research

Human Applications Lab (HAL) staff perform translational Tumor Immunology research for internal projects and biopharmaceutical sponsors. Expert staff are trained in GDP, GLP, and cGMP regulations in order to provide services like cell processing, technology transfer, process scale-up, and other IND-enabling solutions.

Learn More

In The News

Dr. John Powderly Heads Discussion Group at openEHR International and HL7’s 2026 “Converge and Collaborate” Meeting

Converge and Collaborate – 5/14/26

On May 12th and 13th in Dublin, Ireland, openEHR International and HL7 (Health Level Seven) hosted their second annual in-person meeting called “Converge and Collaborate”.  With an overall focus on cancer treatment support, this meeting also had the broader aim of increasing the collaborative agenda at the heart of these two organizations, which is improving interoperability for healthcare data exchange.

Dr. John Powderly, President and CEO of both Carolina BioOncology Institute and BioCytics, led a working group discussion around the idea of the convergence of Clinical Research and Informatics. He was also able to explain to an interested audience about the openEHR Affiliate Program, which allows any country or specific field in the medical/health sciences to form a group as part of openEHR International.  These Affiliate Groups help with digital transformation initiatives in all areas where clinical data standards are used or needed.

Dr. Powderly Keynote Speaker at “Hope is Not a Workflow” Symposium

Hope is Not a Workflow – 3/25/26

Dr. Powderly was recently a Keynote Speaker at an event organized by “Hope is Not a Workflow” cell and gene therapy (C&GT) stakeholder collective partnership. Taking place on March 25, 2026, in Research Triangle Park, the daylong symposium focused on advancing manufacturing for C&GT.

Full Article

Dr. Powderly’s Episodes on the “TIL Talks” Podcast

TIL Talks by Chris White – 2/13/26

Dr. Powderly has been a guest on the podcast “TIL Talks” with host Chris White, a mucosal melanoma survivor, on several occasions over the past few months. Topics discussed include cell therapy, neoantigens, tumor infiltrating lymphocytes, checkpoint inhibitors, clinical trials, and patient awareness, among many other points of conversation related to cancer and cancer treatments.
Please see the list of episodes in the article available via the link below that provides the subject of each conversation and a link to a YouTube video recording of the full-length podcasts.

Full Article

BioCytics Successfully Completes a Key Regulatory Milestone with Recent FDA INTERACT Meeting

BioCytics INTERACT Meeting – 11/18/25

Huntersville, NC, November 18, 2025—BioCytics is pleased to announce  they successfully reached a regulatory milestone for de-risking clinical development plans with a productive FDA INTERACT meeting during which they discussed manufacturing immune cell therapies at the point of care.

Full Press Release
See All News

View Our Facilities